Pethema Foundation

This study tests a combination of four drugs (selinexor, bortezomib, dexamethasone, and daratumumab) in 62 adults with multiple myeloma that has returned or not responded to prior treatments. The goal is to see how many patients achieve a significant reduction in cancer. Because …

This study tests a new combination of three drugs (belantamab mafodotin, carfilzomib, and dexamethasone) in people whose multiple myeloma has returned and stopped responding to a previous treatment. The goal is to find the safest dose and see how well it controls the cancer. Abou…

This study tests a new drug, belantamab mafodotin, combined with standard therapy (VRd) in 50 adults newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if the combination is safe and effective. Patients receive several cycles of …

This study tests two new drug combinations (teclistamab plus daratumumab and talquetamab plus daratumumab) in 30 people with newly diagnosed high-risk multiple myeloma. The goal is to see if these treatments can make the cancer undetectable after initial therapy. Participants wil…